Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?224
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”108
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling97
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment63
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment60
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment57
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting50
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy46
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis41
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment39
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children34
Advancing Methods to Measure and Reward Healthcare Innovation32
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation31
Bayesian Meta-Analysis: A Practical Introduction30
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA30
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States29
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy29
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned29
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)29
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review28
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions28
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 28
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies27
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling25
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS25
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review25
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer25
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review25
0.06377100944519